Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings Inc (ASRT) is a pharmaceutical innovator specializing in neurology and specialty medicines, offering investors comprehensive news coverage through this dedicated hub. Access real-time updates on FDA-approved therapies, strategic partnerships, and financial developments shaping this dynamic healthcare company.
This resource provides verified press releases and analysis-free announcements covering earnings reports, product launches, and regulatory milestones. Track ASRT's progress in neurology treatments and oncology initiatives like Rolvedon through primary source documentation.
Key updates include acquisition activities, licensing agreements, and commercial strategy developments. Investors gain direct access to the company's official communications regarding market expansion, payor contracting progress, and distribution network enhancements.
Bookmark this page for unfiltered access to Assertio's latest developments in specialty pharmaceuticals. Monitor their focused approach to neurological care and orphan drug commercialization through timely, regulation-compliant disclosures.
Assertio Holdings, a pharmaceutical company listed on NASDAQ under the ticker ASRT, announced on July 9, 2024, the issuance of inducement grants to four new employees. Effective from July 1, 2024, these grants comprise 44,575 restricted stock units (RSUs) and 142,910 stock options. The inducement grants are made in accordance with NASDAQ Listing Rule 5635(c)(4) and are intended to encourage the new hires' entry into the company. The RSUs and options have terms similar to those in Assertio's 2014 Omnibus Incentive Plan. The stock options carry an exercise price of $1.19 per share, the closing price on the grant date, and will vest over three years starting from the first anniversary of the grant date.
Assertio Holdings has awarded its new CEO, Brendan P. O’Grady, 500,000 restricted stock units (RSUs) and 1,800,000 stock options as of May 31, 2024.
The stock options, which have an exercise price of $0.99 per share, and RSUs will vest equally over three years. These grants are in accordance with NASDAQ Listing Rule 5635(c)(4) and are material to Mr. O’Grady’s employment with Assertio.
Assertsio is a pharmaceutical company specializing in differentiated products.
Assertio Holdings, a pharmaceutical company known for its commercial capabilities and unique product offerings, announced its participation in the Sidoti Small Cap Conference on June 12, 2024. The event will be held virtually, with Ajay Patel, the Chief Financial Officer, presenting at 10:45 am Eastern Time. Investors can access the presentation through a webcast available on Assertio's investor relations website. Additionally, 1x1 meetings can be scheduled via Sidoti representatives or by contacting Assertio's investor relations.
On May 29, 2024, Assertio announced the appointment of Brendan P. O’Grady as the new CEO and a board member. O'Grady, with over 30 years in the pharmaceutical industry, has a strong record of accelerating sales growth and profitability. Most recently, he was CEO of Glenmark Pharmaceuticals' Global Formulations business, focusing on new product launches and market growth. His previous roles include key positions at Amwell and Teva Pharmaceuticals, where he drove significant growth and productivity. The Board expressed confidence in O'Grady's leadership to drive Assertio's strategic growth and diversification.
Assertio Holdings announced that CFO Ajay Patel will participate in the Benchmark & Company Healthcare House Call Virtual Conference on May 21-22, 2024. Assertio, listed on Nasdaq under the ticker ASRT, specializes in providing differentiated pharmaceutical products. Investors interested in scheduling a meeting can do so through their Benchmark representative or by contacting Assertio's investor relations.
The Buxton Helmsley Group (BHG), an investment fund manager, released a letter from Rumbi B. Petrozzello, a Certified Fraud Examiner, highlighting disclosure failures and deficiencies by the Board of Assertio Holdings (NASDAQ: ASRT). The letter presents significant concerns, urging stockholders to vote against all directors at the upcoming annual meeting on May 23, 2024. Petrozzello's analysis reveals issues like a steep 75% drop in intangible asset value post-Spectrum Pharmaceuticals acquisition, evasive responses from Assertio's management, and insufficient disclosures on contingent liabilities. BHG proposes independent investigation and has nominated Petrozzello to the Board, advocating for new oversight to protect investor interests.
Assertio Holdings (Nasdaq: ASRT), a pharmaceutical company, announced that its Chief Financial Officer, Ajay Patel, will present at the Alliance Global Partners Virtual Healthcare Company Showcase on May 21, 2024, at 3:40 p.m. Eastern Time. The presentation will provide an overview of Assertio's business and will be accessible through AGP's healthcare equity research team. Interested investors can join by contacting their AGP representative or Assertio investor relations. Further details will be available on the day of the event at https://investor.assertiotx.com.
The Buxton Helmsley Group (BHG) urges Assertio stockholders to vote against all director nominees at the upcoming annual meeting on May 23, 2024. BHG criticizes Assertio’s board for failing in oversight, inadequate disclosures, and poor strategic decisions, including a costly acquisition of Spectrum Pharmaceuticals. Analysts have dropped coverage of Assertio, citing a loss of faith in leadership. BHG proposes adding two new directors to bring better oversight and restore value for stockholders. The group also recommends strategic alternatives, including a possible sale to enhance operating profit.
Assertio Holdings, Inc. will present at the Citizens JMP Life Sciences Conference in New York City on May 13, 2024. Ajay Patel, Chief Financial Officer, will lead the presentation at 12:00 pm Eastern Time. Investors can request meetings with the Company through JMP representatives or contact Assertio investor relations. Presentation information will be available on the event day at https://investor.assertiotx.com. To listen to the webcast, connect to the website link 15 minutes before the live webcast.
Assertio Holdings, Inc. reported strong first-quarter financial results, with net product sales of $31.9 million. Rolvedon product sales increased, while Indocin sales decreased due to generic competition. The company's gross margin was 65%, SG&A expenses decreased, and adjusted EBITDA improved. Assertio generated $7.5 million in cash flow, ending the quarter with $80.7 million in cash and cash equivalents. The company reiterated its 2024 financial guidance of $110-125 million in net product sales and $20-30 million in adjusted EBITDA.
FAQ
What is the current stock price of Assertio Holdings (ASRT)?
What is the market cap of Assertio Holdings (ASRT)?
